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Abstract
[Ag2(NH3)2(salH)2] (salH2¼ salicylic acid) was synthesised from salicylic acid and Ag2O in concentrated aqueous NH3 and the
dimeric Ag(I) complex was characterised using X-ray crystallography. The complex is centrosymmetric with each metal coordinated
to a salicylate carboxylate oxygen and to an ammonia nitrogen atom in an almost linear fashion. The two [Ag(NH3)(salH)] units in
the complex are linked by an Ag–Ag bond. Whilst metal-free salH2 did not prevent the growth of the fungal pathogen Candida
albicans [Ag2(NH3)2(salH)2], [Ag2(salH)2] and some simple Ag(I) salts greatly inhibited cell reproduction. SalH2,
[Ag2(NH3)2(salH)2] [Ag2(salH)2] and AgClO4 produced a dose-dependent cytotoxic response against the three human derived
cancer cell lines, Cal-27, Hep-G2 and A-498, with the Ag(I)-containing reagents being the most effective.
 2004 Elsevier Inc. All rights reserved.
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1. Introduction
In our efforts to develop new metal-based drugs for
inhibiting the growth of the fungal pathogen Candida
albicans, and also for deterring the proliferation of
mammalian cancer cells, the most effective metal com-
plex to emerge to date is the Ag(I) complex [Ag(phen-
dio)2]ClO4 (phendio¼ 1,10-phenanthroline-5,6-dione)
[1]. The complex has a minimum inhibitory concentra-
tion (MIC) against C. albicans of 0.5 lg cm3 (0.3 lM)
and tests on cultured human cancer cells produced an
IC50 (the concentration that inhibited growth by 50%)
value of 0.025 lg cm3 (0.40 lM). These findings for the
Ag(I) complexes were a marked improvement on values
obtained using other transition metals complexed by
phendio or 1,10-phenanthroline [1–3] and have promp-
ted investigations into the preparation, characterisation
and testing of other Ag(I) complexes. The present paper
details the synthesis, X-ray crystal structure and bio-
logical activity of the dimeric Ag(I) complex
[Ag2(NH3)2(salH)2] (salH2¼ salicylic acid).
2. Results and discussion
The method used for preparing [Ag2(NH3)2(salH)2]
was quite similar to that employed for the preparation
of the known non-amine analogue [Ag2(salH)2] [4–6].
[Ag2(NH3)2(salH)2] was obtained from a suspension of
Ag2O in water to which was added concentrated aque-
ous NH3 followed by salicylic acid (salH2). On the other
hand, [Ag2(salH)2] was prepared in an 80:20 etha-
nol:water solvent mixture to which was added salH2,
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AgNO3 and concentrated aqueous NH3. The X-ray
crystal structure of [Ag2(NH3)2(salH)2] is shown in
Fig. 1 and selected bond lengths and angles are given in
Table 1. The complex is dimeric, centrosymmetric and
close to planar. Each metal is coordinated to a salicylate
carboxylate oxygen (Ag–O¼ 2.170 A) and to an am-
monia nitrogen atom in an almost linear fashion
{O(3)–Ag–N(1)¼ 175.37(5)}. A similar monodentate
carboxylate coordination has been reported for the
polymeric Ag(I) salicylate complex [Ag(l3-hmt)(salH)] 
H2O (hmt¼ hexamethylenetetramine) [7]. The Ag–O
distance in [Ag2(NH3)2(salH)2] is shorter than those in
the syn–syn bis(carboxylate-bridged) dimer [Ag2(salH)2]
(2.181, 2.202 A) [5,6]. In [Ag2(NH3)2(salH)2], an almost
linear N–Ag–O geometry is completed by coordination
of an ammonia molecule (Ag–N¼ 2.137 A).
In [Ag2(NH3)2(salH)2], the two [Ag(NH3)(salH)]
units are linked by an Ag–Ag bonding interaction,
supported by hydrogen-bonding between the coordi-
nated O atom of one unit and an ammonia hydrogen
atom of the other. The essentially planar conformation
is the result of stabilisation due to intramolecular hy-
drogen-bonding interactions between the ortho-substi-
tuted phenol and the uncoordinated carboxylate
oxygen. In essence, the two monomers aggregate ‘‘head-
to-tail’’ to allow for this hydrogen-bonding. Such hy-
drogen-bonding interactions have been implicated in the
formation of some complexes exhibiting auriophilicity
[8]. In contrast to the structure of [Ag2(NH3)2(salH)2],
the silver(I) benzoates with no ortho-hydroxyl substitu-
ents deviate markedly from planarity [9]. The Ag–Ag
bond (3.069 A) in [Ag2(NH3)2(salH)2] is slightly longer
than that found in [Ag2(salH)2] (2.855 A) implying that
the ligand architecture of the syn–syn bridged dimers in
the latter species facilitates a closer approach of the
silver ions [5,6]. However, the Ag–Ag distance in
[Ag2(NH3)2(salH)2] is still indicative of an Ag–Ag ar-
gentophilic interaction when compared to a value of
2.89 A for the interatomic distance in metallic silver [10].
It has been speculated that such an attractive interaction
between the Ag(I) d10 cations is due to hybridisation of
the metal 4d orbital with the higher energy 5s and 5p
orbitals, which converts the closed-shell repulsion into a
weak attractive interaction [11–13]. The 1H NMR
spectrum of [Ag2(NH3)2(salH)2] in DMSO indicates
that no ligand exchange of the complex with DMSO
takes place.
SalH2, [Ag2(salH)2] and [Ag2(NH3)2(salH)2] were
screened for their ability to inhibit the growth of C. al-
bicans (Table 2). Whilst metal-free salH2 was essentially
ineffective at controlling the growth of the organism,
[Ag2(salH)2] did show quite marked activity. However,
the ammonia complex [Ag2(NH3)2(salH)2] displayed an
approximately tenfold superior activity at controlling
yeast cell proliferation. Previous investigations into the
anti-microbial activity of [Ag2(salH)2] suggested that its
effects were due to the presence of free Agþ ions in a
fashion similar to AgNO3 [14]. Given the poorly water-
soluble nature of [Ag2(salH)2] (ca. 0.1 g per 100 cm
3 at
pH 6.5) compared to AgNO3 (250,000 mg per 100 cm
3
at pH 7), such a reasoning might be expected to account
for the superior activity of AgNO3 as the completely
dissociated salt would give rise to a much higher con-
centration of free Agþ ions in the test media [14].
However, on a cautionary note, it must be emphasised
that comparisons of solubilities of compounds in water
with those in test media are likely to be unreliable given
the multi-component nature of growth media. It must
also be stressed that the present activity data cannot be
rigorously interpreted to mean that the salicylate com-
plexes remain intact throughout the screening protocol
Fig. 1. X-ray crystal structure of [Ag2(NH3)2(salH)2].
Table 1
Selected bond lengths (A) and angles () for [Ag2(NH3)2(salH)2]
Ag(1)–N(1) 2.1367(17)
Ag(1)–O(3) 2.1699(14)
Ag(1)–O(2) 2.7577(14)
Ag(1)–Ag(1)#1 3.0685(4)
N(1)–Ag(1)–O(3) 175.37(5)
N(1)–Ag(1)–O(2) 132.88(5)
O(3)–Ag(1)–O(2) 51.74(4)
N(1)–Ag(1)–Ag(1)#1 90.47(4)
O(3)–Ag(1)–Ag(1)#1 84.90(4)
O(2)–Ag(1)–Ag(1)#1 136.62(3)
Table 2
MIC data for C. albicans
Compound MIC (lM)
AgCH3CO2 [1] 30
AgNO3 [1] 30
AgClO4 [1] 44
salH2 >724
[Ag2(salH)2] 5.0
[Ag2(NH3)2(salH)2] 0.5
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and that the MIC values reflect exactly the effects of
either the free Agþ ion or the Ag(I) complexes. The
small variations on the MIC values could result from
common metabolites for the free metal ion and the
complexes, which might be generated after incorpora-
tion into the cells. Either, metabolism of the complexes
leading to free Agþ ion, or complexation of Agþ and
ligand displacement of the salH and NH3 by a higher
affinity ligand, extra- or intra-cellularly, could lead to
the common results. It seems likely that the ammonia
ligands in [Ag2(NH3)2(salH)2] are in some way respon-
sible for the superior activity of this complex compared
to that of [Ag2(salH)2], which does not have any coor-
dinated NH3. It is noteworthy that the inhibitory effect
of [Ag2(NH3)2(salH)2] is on a parity with that of the
extremely active complex [Ag(phendio)2]ClO4 [1].
Previous studies on the mode of action of Ag(I)
complexes have revealed that their anti-fungal activity is
mediated though disruption of mitochondrial function
[3]. For example, exposure of C. albicans to
[Ag2(phen)3(mal)]  2H2O (phen¼ 1,10-phenanthroline;
mal¼malonic acid dianion) leads to a reduction in
respiration with a concomitant depletion in the quantity
of ergosterol in the fungal cell membrane. Ergosterol
synthesis is disrupted because a depletion in respiration
leads to a loss in NADH–NADPH cycling, which is
required for the action of one of the enzymes in ergos-
terol biosynthesis [15]. The adverse effect on respiration
appears to be due to the disruption of the synthesis of
cytochromes (especially cytochrome aa3, components of
which are mitochondrially encoded) [3]. Cytochromes
form an integral part of the electron transfer pathway
essential for aerobic respiration and consequently a re-
duction in their synthesis adversely affects respiration. In
addition, Ag(I) complexes also induce apoptosis (pro-
grammed cell death) in fungal and mammalian cells
which may be a direct result of their action on the cell or
a secondary effect arising from their disruption of res-
piration. Cells treated with [Ag2(phen)3(mal)]  2H2O
show extensive DNA fragmentation, mitochondrial
disruption and retraction of the cytoplasm [16].
One feature of the [Ag2(phen)3(mal)]  2H2O-medi-
ated reduction in respiration and ergosterol synthesis is
that this renders cells more tolerant of the polyene anti-
fungal prescription drug amphotericin B [17]. Ampho-
tericin B is one of the principal anti-fungal drugs used
for the treatment of systemic, life-threatening mycoses
and functions by binding to ergosterol in the cell
membrane and creating pores through which intracel-
lular constituents escape [18,19]. The reduced level of
ergosterol in treated cells leads to a higher tolerance to
this anti-fungal drug and may have implications for the
treatment of fungal infections.
Ag(I) complexes demonstrate strong anti-fungal
properties and appear to target the mitochondrion. This
has the effect of reducing the amount of ergosterol in the
cell membrane and may also trigger the process of ap-
optosis. Thus, such complexes may have therapeutic
potential for the treatment of superficial fungal infec-
tions and they manifest a mode of action distinct to that
of the conventional anti-fungal drugs [20] making them
potentially applicable in situations where resistance to
these prescription drugs has emerged to compromise
therapy [21].
The chemotherapeutic potential of salH2, AgClO4
and the two salicylate complexes, [Ag2(salH)2] and
[Ag2(NH3)2(salH)2], was determined against the three
human derived cancer cell lines, Cal-27, Hep-G2 and A-
498. Profiles of cell viability against drug concentration
were established (Figs. 2–4) from which IC50 values were
Conc (μM)
0.01 0.1 1 10 100 1000 10000
Vi
ab
ilit
y
a
s
%
co
n
tro
l
0
20
40
60
80
100
120
[Ag2(salH)2]
salH2
[Ag2(NH3)2(salH)2]
AgClO4
Fig. 2. Effects of salH2, [Ag2(salH)2], [Ag2(NH3)2(salH)2] and AgClO4
on the viability of Cal-27 cancer cells following continuous incubation
with increasing drug concentration (0.1–1000 lM) for 96 h. Bars in-
dicate standard error of the mean (SEM) and results were statistically
significant from control at p < 0:05.
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Fig. 3. Effects of salH2, [Ag2(salH)2], [Ag2(NH3)2(salH)2] and AgClO4
on the viability of Hep-G2 cancer cells following continuous incuba-
tion with increasing drug concentration (0.1–1000 lM) for 96 h. Bars
indicate standard error of the mean (SEM) and results were statisti-
cally significant from control at p < 0:05.
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calculated (Table 3). For all cell lines a concentration-
dependent cytotoxic response was observed for all
compounds. Whilst the metal-free carboxylic acid salH2
had a mild cytotoxic effect across the three cell lines, the
Ag(I)-containing species, AgClO4, [Ag2(salH)2] and
[Ag2(NH3)2(salH)2], were all highly toxic. However, this
apparent Ag-related cytoxic effect is significant at drug
concentrations greater than 10 lM, and in all of the cell
lines studied. Close similarities were found in the via-
bility versus concentration profiles for AgClO4,
[Ag2(salH)2] and [Ag2(NH3)2(salH)2] across all three cell
lines (Figs. 2–4). Whilst there is no discrimination in the
activity of [Ag2(salH)2] across the three cell lines, both
AgClO4 and [Ag2(NH3)2(salH)2] offer some bias to-
wards inhibiting the growth of Hep-G2 cells.
3. Experimental
Chemicals, cell culture reagents and media were
purchased from commercial sources and were used
without further purification. [Ag2(salH)2] was prepared
in accordance with the literature procedure [4–6]. In-
frared spectra of solids (in a KBr matrix) were recorded
in the region 4000–400 cm1 on a Nicolet FT-IR Impact
400D infrared spectrometer and 1H NMR spectra were
run on a Bruker Avance 300 MHz instrument. Micro-
analytical data were provided by the Microanalytical
Laboratory, National University of Ireland, Cork,
Ireland.
C. albicans ATCC 10231 was obtained form the
American Type Culture Collection, (Manasas, VA,
USA). Cultures were grown on Sabouraud dextrose
agar (SDA) plates at 37 C and maintained at 4 C for
short-term storage. Cultures were routinely sub-cultured
every 4–6 weeks. Cultures were grown to the stationary
phase (approximately 1 108 cells cm3) overnight at 30
C and 200 rpm in minimal medium (MM) (2% w/v
glucose, 0.5% w/v yeast nitrogen base (without amino
acids or ammonium sulphate), 0.5% w/v ammonium
sulphate). Solutions of water-soluble test salts were
prepared by dissolving the salt (0.02 g) in distilled water
(100 cm3) to yield a stock solution with a concentration
of 200 lg cm3. Doubling dilutions of this stock solution
were made to yield a series of test solutions. The water-
insoluble Ag(I) complexes, [Ag2(salH)2] and
[Ag2(NH3)2(salH)2], were made up as suspensions (0.02
g) in water (100 cm3) to give stock suspensions. With
vigorous agitation of these suspensions doubling dilu-
tions were made to give a series of test suspensions.
Minimum inhibitory concentrations (MICs) were then
determined using the broth microdilution method [2,3].
Cytotoxicity assays were performed using three hu-
man malignant model cell lines in order to assess the
cancer chemotherapeutic potential of metal free Sal and
its metal complexes. Therefore, squamous carcinoma
tongue (Cal-27), hepatocellular carcinoma (Hep-G2)
and kidney adenocarcinoma (A-496) cell lines were
purchased from the ATCC. All cell lines were grown as
monolayers in Eagle’s minimum essential medium,
supplemented with 2 mM L-glutamine and Earle’s bal-
anced salt solution, containing 1.5 g dm3 sodium bi-
carbonate, 0.1 mM non-essential amino acids, 1.0 mM
sodium pyruvate, 100 U cm3 penicillin and 100 lg cm3
streptomycin supplemented to contain 10% (v/v) foetal
bovine serum (Flow laboratories, Herts, UK). All cells
were grown at 37 C in a humidified atmosphere, in the
presence of 5% CO2 and were in the exponential phase
of growth at the time of assay. Cytotoxicity was assessed
using the MTT assay. Each of the three cell lines (100 ll)
were seeded at a density of 5 104 cells cm3 into sterile
96-well flat-bottomed plates (Falcon Plastics, Becton
Dickinson) and grown in 5% CO2 at 37 C. Test com-
pounds were dissolved in DMSO and diluted with cul-
ture media. The maximum percentage of DMSO present
in all wells was 0.2% (v/v). Each drug solution (100 ll)
was added to replicate wells in the concentration range
of 0.1–1000 lM and incubated for 96 h. A miniaturised
viability assay using 3-(4,5-dimethylthiazol-2-yl)-2,5-di-
phenyl tetrazolium bromide (MTT) was carried out ac-
Table 3
IC50 values (lM) (meanSEM, n ¼ 5) for compounds against Cal-27,
Hep-G2 and A-498 cancer cells
Compound Toxicities (IC50 lM)
Cal-27 Hep-G2 A-498
salH2 700 40 1000 0 900 141
AgClO4 56 0 8 1 45 2
[Ag2(salH)2] 27 2 20 1 18 2
[Ag2(NH3)2(salH)2] 51 11 9 0 32 7
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Fig. 4. Effects of salH2, [Ag2(salH)2], [Ag2(NH3)2(salH)2] and AgClO4
on the viability of A-498 cancer cells following continuous incubation
with increasing drug concentration (0.1–1000 lM) for 96 h. Bars in-
dicate standard error of the mean (SEM) and results were statistically
significant from control at p < 0:05.
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cording to the method described by [22]. The IC50 value,
defined as the drug concentration causing a 50% re-
duction in cellular viability, was calculated for each
drug. Each assay was carried out using five replicates
and repeated on at least three separate occasions. Via-
bility was calculated as a percentage of solvent-treated
control cells and expressed as a percent (%) of the
control. The significance of any reduction in cellular
viability was determined using one-way ANOVA
(analysis of variance). A probability of 0.05 or less was
deemed statistically significant.
4. [Ag2(NH3)2(salH)2]
The following procedure was conducted with the ex-
clusion of light. To a suspension of Ag2O (0.5 g, 2.0
mmol) in water (10 cm3) was added, dropwise, concen-
trated aqueous NH3 until all solid had dissolved. Sali-
cylic acid (salH2) (0.55 g, 4.0 mmol) was added and the
solution stirred at room temperature for 0.5 h. The so-
lution was evaporated to dryness and the grey solid re-
suspended in ethanol (5 cm3). The solid was filtered off,
washed with small portions of chilled water, ethanol and
ether and then air-dried. Yield: 0.83 g (79%). The sample
was stored with the exclusion of light. The sample was
soluble in hot acetonitrile and in DMSO, and was es-
sentially insoluble in water. Anal. Calc.: C, 32.25; H,
3.08; N, 5.34%. Found: C, 32.23; H, 3.02; N, 5.05. IR
(KBr): 3457, 3235, 2927, 1646, 1596, 1492, 1461, 1393,
1338, 1301, 1252, 1153, 1030, 861, 812, 750, 701, 670,
535 cm1. 1H NMR (ppm DMSO): 14.47 (s, 1H, OH),
7.78 (d, 1H, phenyl ring), 7.24 (t, 1H, phenyl ring), 6.71
(m, 2H, phenyl ring), 3.01 (s, 3H, NH3). Crystals suit-
able for X-ray analysis were obtained following recrys-
tallisation from hot acetonitrile.
4.1. X-ray crystallography
Crystal data for [Ag2(NH3)2(salH)2] were collected at
150(2) K on a Bruker SMART 1000 diffractometer. The
structure was solved by direct methods and refined by
full-matrix least-squares on F 2 using the SHELXTL
suite of programs [23]. All non-hydrogen atoms were
refined with anisotropic atomic displacement parame-
ters. Hydrogen atoms were inserted at calculated posi-
tions using a riding model except for the phenolic
proton, which was located from difference maps and
allowed to refine with a fixed atomic displacement pa-
rameter. Details of the data collection and structure
refinement are given in Table 4.
Supplementary data for [Ag2(NH3)2(salH)2] are
available from the Cambridge Crystallographic Data
Centre, 12 Union Road, Cambridge CB2 1EZ, England
(Fax: +44-1223-336033), on request quoting the depo-
sition number CCDC 224787.
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